Presentation of the results from the Phase 3 AB07015 study in severe asthma at the EAACI 2020 Annual Congress
07/05/2020 – AB Science will present results from its Phase 3 study in severe asthma at the EEACI 2020 Annual Congress
Authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
06/05/2020 – AB Science granted authorization by ANSM to initiate Phase 2 study evaluating masitinib in combination with isoquercetin for the treatment of COVID-19
Annual financial results as of 31 December, 2019
30/04/2020 – AB Science reports its annual financial results as of 31 December, 2019
2017
Monthly disclosure of total outstanding shares and voting rights Dated December 4, 2017 Monthly disclosure of total outstanding shares and voting rights Dated November 7, 2017 Monthly disclosure of total outstanding shares and voting rights Dated October 2, 2017 Monthly disclosure of total outstanding shares and voting rights Dated August 7, 2017 Monthly disclosure of…
2018
Monthly disclosure of total outstanding shares and voting rights Dated December 6, 2018 Monthly disclosure of total outstanding shares and voting rights Dated November 6, 2018 Monthly disclosure of total outstanding shares and voting rights Dated October 3, 2018 Monthly disclosure of total outstanding shares and voting rights Dated September 5, 2018 Monthly disclosure of…
2019
Monthly disclosure of total outstanding shares and voting rights Dated December 2, 2019 Monthly disclosure of total outstanding shares and voting rights Dated November 5, 2019 Monthly disclosure of total outstanding shares and voting rights Dated October 2, 2019 Monthly disclosure of total outstanding shares and voting rights Dated September 3, 2019 Monthly disclosure of…
2020
Monthly disclosure of total outstanding shares and voting rights Dated April 2, 2020 Monthly disclosure of total outstanding shares and voting rights Dated March 4, 2020 Monthly disclosure of total outstanding shares and voting rights Dated February 5, 2020 Monthly disclosure of total outstanding shares and voting rights Dated January 8, 2020
Letter to our stakeholders on COVID-19 pandemic impact on AB Science studies
03/04/2020 – A letter to our stakeholders on COVID-19 pandemic impact on AB Science clinical studies
Summary of webcast with Key Opinion Leaders on masitinib Phase 2B/3 results in Progressive Forms of MS
09/03/2020 – AB Science provides a summary of the live webcast held on March 6 2020 with key opinion leaders on progressive froms of multiple sclerosis
New fundraising of EUR 12.3 million
02/03/2020 – AB Science announces a new fundraising of EUR 12.3 million